ADPT:NSD-Adaptive Biotechnologies Corp (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 7.28

Change

0.00 (0.00)%

Market Cap

USD 1.09B

Volume

1.82M

Analyst Target

USD 51.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. It has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 76.39B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 18.65B
SMMT Summit Therapeutics PLC

N/A

USD 17.01B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing ADPT

ARKG ARK Genomic Revolution ET.. 5.46 % 0.75 %

N/A

USD 1.06B
ARKG:LSE ARK Genomic Revolution UC.. 4.96 % 0.00 %

N/A

USD 9.33M
ARCG:LSE ARK Genomic Revolution UC.. 4.93 % 0.00 %

N/A

USD 9.51M
WELP:LSE HAN-GINS Indxx Healthcare.. 1.24 % 0.00 %

N/A

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.43% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.43% 88% B+ 91% A-
Trailing 12 Months  
Capital Gain 124.69% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 124.69% 95% A 95% A
Trailing 5 Years  
Capital Gain -59.58% 50% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.58% 50% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -30.80% 12% F 6% D-
Dividend Return -30.80% 12% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.51% 69% C- 43% F
Risk Adjusted Return -69.20% 15% F 9% A-
Market Capitalization 1.09B 82% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector